疫苗ETF（159643）盘中涨超2%，医药科技属性强化或成行业新动能

Group 1 - The pharmaceutical and biotechnology industry is experiencing a sustained improvement in prosperity, with innovative drugs entering the 3.0 era, showcasing a leading trend in new targets, technologies, and disease areas in China [1] - Recent positive clinical data for small nucleic acid drugs and the emergence of targeted delivery technologies indicate significant potential in chronic disease areas such as cardiovascular and metabolic diseases [1] - The domestic CRO (Contract Research Organization) orders are showing a trend of increasing volume and price, benefiting from the overseas business development of innovative drugs and a stabilization in financing, with performance expected to improve by 2026 [1] Group 2 - The medical device industry continues to have demand-side potential, with supply-side structural upgrades and accelerated innovation and internationalization, expected to maintain steady growth through 2026 [1] - The exploration of AI in medicine is ongoing, with potential effective business models emerging in areas such as assisted diagnosis and health management [1] - Brain-computer interface technology is undergoing rapid iteration and upgrades, with significant clinical and commercialization advancements anticipated by 2026, marking a new development phase for the industry [1] Group 3 - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in vaccine research, production, and related biotechnology businesses to reflect the overall performance of the biopharmaceutical and research service sectors [1] - This index is characterized by high growth and innovation, focusing on the bioproducts and research service fields [1]